Return to homepagePandemic Pact

Use of natural killer (NK) cells carrying an anti-spike mAb as covid19 therapy

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    ANR

  • Principal Investigator

    Martin VILLALBA

  • Research Location

    France

  • Lead Research Institution

    CHRU de Montpellier

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The CoviNK project, coordinated by Martin Villalba (UMR U1183 Institute of Regenerative Medicine and Biotherapies (IMRB) - CHRU de Montpellier), proposes to use natural killer cells (NK) carrying an anti-spike mAb, for the treatment of COVID -19. The team will be based on an expanded NK (eNK) production protocol patented by Inserm, and on a new approach for stably loading monoclonal antibodies (mAbs) on the membrane of NK cells, currently being developed for the cancer therapy.